Program & vendor performance
Review patient-support program scope, vendor responsibilities, reporting and handoffs for an established brand.
Explore →Canadian market access & launch readiness
Health Canada approval starts your access work. It doesn’t finish it.
New drugs in Canada have waited an average of about 2.5 years between Health Canada approval and a first public drug-plan listing.¹ MediVationsRx helps emerging and mid-sized biopharma, especially international sponsors without a Canadian team, map their private-payer, provincial and patient-support routes and choose the partners to make the launch workable.
Former life sciences CEO50+ product lines launched$15M+ clinical-trial funds managed
WHY CANADIAN ACCESS TAKES PLANNING
Three routes to patients. Only one is slow by design.
Health Canada approval (NOC)
Public drug plans
CDA-AMC reviewpCPA negotiationProvincial listing
≈ 906 daysaverage from Health Canada approval to first public listing, 2018–2023¹
Private payers
Insurer submissionsPrior authorizationCoverage under private plans
Patient support programs
EnrolmentReimbursement navigationBridging support
Can start earlier, depending on product and payer
¹ PMPRB, Factors delaying the public listing of drugs in Canada (2025). Quebec follows a separate INESSS review and RAMQ listing path.
Who we work with
Built for lean teams with a Canadian launch on the calendar.
International sponsors entering Canada
A Health Canada submission pending or a recent approval, and no Canadian affiliate yet, or one still being built.
Discuss your launch →Canadian specialty pharma
A launch in the next 18 months and a market-access team of zero to two people.
Discuss your launch →Biosimilar manufacturers
A product new to Canada or facing provincial switching policies.
Discuss your launch →Best fit: a dated launch within about 18 months, a named commercial or market-access owner, and no access plan in place yet.
The starting engagement
Canada Access & Launch Readiness Assessment
4–6 weeksFixed feeSenior-ledNo patient data needed
A fixed-scope, 4–6 week assessment that gives your commercial team a decision-ready Canadian access plan before you commit launch budget, hire a team or sign a patient-support vendor.
Depending on the scope you choose, you receive:
- An access-route map: public plans, private payers and provincial exception pathways
- A launch timeline showing the decisions and dependencies that drive it
- Your top risks and the assumptions to test first
- Patient-support program requirements and a budget range
- A private-payer strategy and a vendor shortlist with selection criteria
- A 90-day implementation plan with owners and decision gates
Canada Access Route Map
ILLUSTRATIVE SAMPLEProduct X · hypothetical specialty therapy
- Health CanadaApprovedNotice of Compliance received
- CDA-AMC reviewIn progressSubmission filed
- pCPA negotiationPlannedSequenced after recommendation
- Private payersPriority routePrior-authorization criteria mapped
- Provincial exceptionsRoute identifiedExceptional-access criteria reviewed
- Patient supportSpec draftedBridging + reimbursement navigation
Launch decisions: 4 of 6 made
How it works
Four steps. Fixed scope. Decision-ready outputs.
Align
Week 1Confirm the decision owner, product context, launch date and the evidence the plan needs.
You get: agreed scope and success measures.
Assess
Weeks 1–4Map public, private and provincial routes, then review channel, partner and patient-support options with your team.
You get: segments, channels and partner options assessed.
Recommend
Weeks 4–6Deliver the access-route map, risks and partner options as a sequenced plan.
You get: a business case, prioritized options, accountabilities and a launch roadmap with open questions for specialists.
Execute
If agreedFractional commercial leadership or implementation support under a separate written scope.
You get: named owners, priorities and monthly measures.
Illustrative structure. Actual scope and timing are set in a written proposal.
Other biopharma services
Already launched, or need something narrower?
Fractional commercial leadership
Accountable Canadian commercial or launch leadership while you decide on a permanent team.
Explore →Pharmacy-channel strategy
Plan how specialty and community pharmacies fit your product’s channel and support model.
Explore →Clinical trial medication readiness (advisory)
Scoped advice on medication readiness and pharmacy-model questions for defined studies.
Explore →
Leadership
Led by an executive who has launched products and run the pharmacies that dispense them.
Malay Panchal, MBA, RPh, is a former CEO of a TSX Venture-listed life sciences company and former chief revenue officer of an AI and digital-health company. He has launched more than 50 product lines across Canada, the U.S., Europe, South America and Asia, and spent 20+ years running retail pharmacies and medical clinics. Your access plan is built by someone who has seen both the launch decision and the pharmacy counter where coverage problems show up.
- 50+product lines launched across five regions
- $10M+contracted sales from 6 product launches in Canada and the U.S.
- $15M+clinical-trial funds managed across 25 Canadian trials
- 20+ yearsrunning pharmacies and clinics, 10 as an owner-operator
Selected results. Client names are confidential.
Malay scopes and leads every engagement. Contract market-access, regulatory and pharmacist specialists join where the scope requires.
About MediVationsRx →For pharmacy and clinic owners
Running an independent pharmacy or clinic?
Start with a free self-assessment that takes a few minutes, then choose a fixed-scope review of claims, profitability, services or operations.
Commercial and market-access advisory only. We work alongside your support-program, distribution and pharmacy partners and never handle patient information. What we do and what we coordinate →
Questions
Frequently asked questions
Who is the assessment for?
Commercial and market-access leaders at emerging and mid-sized biopharma with a Canadian launch in about the next 18 months, especially international sponsors without a Canadian team.
How long does it take, and how is it priced?
Four to six weeks. The fee is fixed for the scope you choose and agreed in a written proposal before work starts.
Do you replace our patient-support provider or market-access consultancy?
No. We help you decide what you need, then choose and manage the right partners. Where an established provider or specialist is the better fit, we’ll say so.
Do you prepare regulatory or reimbursement submissions?
We don’t prepare Health Canada submissions. Health technology assessment and pricing work is scoped with qualified specialists where your plan needs it.
What do you need from us to start?
Your product context, launch timing and a decision owner. Public and non-confidential information is enough to begin. We never need patient data.
Let’s discuss your launch
Have a Canadian launch in the next 18 months?
Tell us about the product, the timing and your current Canadian team. We’ll reply with whether the assessment fits and a proposed scope.